Genetic anticipation in a special form of hypertrophic cardiomyopathy with sudden cardiac death in a family with 74 members across 5 generations

Xiyiing Guo, MDA, Chaomei Fan, MDA∗, Yanping Wang, MDA, Miao Wang, PhD, A∗, Chi Cai, MDA, Yinjian Yang, MDA, Shihua Zhao, MDC, Fujian Duan, MDD, Yishi Li, MDA

Abstract
Hypertrophic cardiomyopathy (HCM) is the most common heritable heart disease. The genetic anticipation of HCM and its associated etiology, sudden cardiac death (SCD), remains unclear. The aim of this study was to investigate the mechanism underlying the genetic anticipation of HCM and associated SCD.

An HCM family including 5 generations and 74 members was studied. Two-dimensional echocardiography was performed to diagnose HCM. The age of onset of HCM was defined as the age at first diagnosis according to hospital records. The information on SCD was confirmed by verification by ≥2 family members and a review of hospital records. Whole-genome sequencing was performed on 4 HCM subjects and 1 healthy control in the family. The identified mutations were screened in all available family members and 216 unrelated healthy controls by Sanger sequencing.

The median ages of onset of HCM were 63.5, 38.5, and 18.0 years in members of the second, third, and fourth generations of the family, respectively, and the differences between the generations were significant (P < 0.001). The age at SCD also decreased with each subsequent generation (P < 0.05). In particular, among the third-generation family members, SCD occurred between 30 and 40 years of age at approximately 8 AM, whereas among the fourth-generation family members, all 5 males who experienced SCD were 16 years of age and died at approximately 8 AM. The sarcomere gene mutations MYH7-A719H and MYOZ2-L169G were detected in the HCM individuals in this pedigree. Increases in the number of mutations and the frequency of multiple gene mutations were observed in the younger generations. Moreover, a structural variant was present in the HCM phenotype-positive subjects but was absent in the HCM phenotype-negative subjects.

HCM may exhibit genetic anticipation, with a decreased age of onset and increased severity in successive generations. Multiple gene mutations may contribute to genetic anticipation in HCM and thus may be of prognostic value.

Abbreviations: ECG = electrocardiogram, HCM = hypertrophic cardiomyopathy, LV = left ventricular, SCD = sudden cardiac death, SNP = single-nucleotide polymorphism, SV = structural variant, WGS = whole-genome sequencing.

Keywords: genetic anticipation, hypertrophic cardiomyopathy, sudden cardiac death, whole-genome sequencing

1. Introduction
Hypertrophic cardiomyopathy (HCM), the most common hereditary cardiac disease, affects 1 in every 500 people in the general population and represents a major cause of sudden cardiac death (SCD) in adolescent athletes.[1] It exhibits vast genetic and clinical heterogeneity and is typically inherited in an autosomal dominant manner.[2] More than 1400 variations in ≥27 genes encoding proteins in cardiac sarcomeres have been reported to be responsible for (or associated with) HCM over the past 20 years.[3] Most HCM patients are diagnosed between the ages of 30 and 60, and this disease is relatively infrequent in individuals younger than 25 years of age.[4] Genetic anticipation is a phenomenon by which the age of onset of an inherited disorder decreases and/or the phenotypic severity increases in successive generations.[5] The occurrence of this phenomenon has been well established in a number of inherited neurodegenerative disorders and other autosomal dominant genetic diseases and has long been suspected in HCM. Patients with a family history of HCM tend to exhibit symptoms earlier and to have more severe symptoms, such as an increased degree of myocardium hypertrophy or premature...
SCD, compared with those without a family history. Czechs et al described the anticipation phenomenon in HCM patients; however, the underlying genetic mechanisms remain unclear.[6] Gene mutations may occur when specific genetic regions (including noncoding regions) are passed on to subsequent generations. Here, we report the clinical and genetic findings for a multigeneration Chinese family in which genetic anticipation coexists with premature SCD. This is the first study to reveal a genetic basis for the anticipation phenomenon in HCM.

2. Methods

2.1. Study population, pedigree characteristics, and diagnostic criteria for HCM

We identified a large Chinese family with HCM through Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China). This family included 5 generations and a total of 74 members (41 males and 33 females). The proband was a 47-year-old male (III:15, Fig. 1). We examined all living family members.
members by transthoracic echocardiography. Considering the apparent family history of HCM, the disease was diagnosed based on a left ventricular (LV) wall thickness ≥13 mm in adults or a thickness ≥2 standard deviations above the predicted mean in children at the end of the diastolic period. All measurements were performed during an average of 3 cardiac cycles for patients with normal sinus rhythm and a minimum of 5 beats in patients with atrial fibrillation to account for interbeat variability. The LV wall thickness and LV dimensions were measured perpendicular to the long axis of the left ventricle by M-mode imaging and 2-dimensional echocardiography.

Other factors known to cause the observed hypertrophy were not observed in this family. Pulsed-wave, continuous-wave, and color Doppler were used as necessary for accurate definitions of obstruction. SCD was defined as the occurrence of collapse in the absence of or within 1 hour of the onset of symptoms in patients who had previously experienced a relatively stable or uneventful clinical course. The age of onset of HCM was defined as the age at first diagnosis in the hospital setting. The age and time of SCD were confirmed by verification with ≥2 family members and by reviewing hospital records.

This study was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants, and all experiments were approved by the Research Ethics Board of Fuwai Hospital.

2.2. Whole-genome sequencing

We selected an immediate family member from each generation (II:3, III:15, and IV:13) to identify genetic alterations. An individual with collateral consanguinity to the proband, IV:22, was also selected to confirm the potential pathogenic mutations. Individual IV:14 had a normal phenotype and was selected as a control for whole-genome sequencing (WGS). Genomic DNA (1.5 μg) was sheared into ~350-bp fragments using a Covaris S220 sonicator. The concentrations and size distributions of the DNA libraries were determined using an Agilent BioAnalyzer DNA 1000 chip. Paired-end 150-bp reads from the DNA libraries were sequenced using an Illumina HiSeq X system (Illumina, San Diego, CA) according to the manufacturer’s instructions. After we performed quality control measures to validate the raw data, the cleaned sequencing reads were mapped to the reference genome (UCSChg19) to obtain the original mapping results. Picard, GATK, and SamTools were used to remove duplicate reads. In addition, the SamTools mpileup and bcftools were used for variant calling and to identify single-nucleotide polymorphisms (SNPs) and indels. Further, Control-FREEC was used to identify copy number variants, and Crest was used to detect structural variants (SVs).

2.3. Pathogenic variant detection

To search for potential pathogenic mutations, we first removed all noncoding and synonymous variants. Then, rare (frequency <0.5%) nonsynonymous, loss-of-function, and splice-site variants were selected as candidates. Next, we screened all known cardiovascular disease-associated genes (including an arrhythmia- and cardiomyopathy-associated gene in the Pan Cardiomyopathy Panel) to identify potential pathogenic mutations among the detected variants. Potential pathogenic mutations were additionally required to be absent from publicly available databases, including dbSNP, the 1000 Genomes Project, and the National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project (ESP 6500). For the SNPs, we also used SIFT and PolyPhen-2 software programs to predict their protein structures and functional alterations. The detected potential pathogenic mutations were validated by Sanger sequencing with an ABI3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA) in the corresponding individuals to avoid false-positive results in WGS. The novel mutations were confirmed in 216 unrelated healthy individuals.

2.4. Cosegregation analysis of the family

Shared variants that were detected in the affected individuals but not in the healthy individuals in this family were selected and further validated by Sanger sequencing in all family members. These mutations were considered pathogenic/nonpathogenic based on the preponderance of evidence obtained from cosegregation analysis (whether the identified mutations cosegregated with the HCM phenotype). The novel identified mutations were also confirmed in 216 unrelated healthy individuals.

2.5. Statistical analysis

Continuous variables are expressed as the median and interquartile range. Nonparametric tests were used to compare the age of onset of HCM. Parent–child generations with HCM were compared using the Wilcoxon rank-sum test. The age of onset of HCM was compared across generations using the Kruskal–Wallis test. For subjects with different numbers of mutations, the age of onset of HCM, echocardiographic parameters, and predicted probability of SCD at 5 years were compared using the Kruskal–Wallis test, and the rate of cardiovascular events was compared using Fisher exact test. Analyses were conducted using SPSS 16.0 software (SPSS Inc, Chicago, IL). A P value <0.05 was considered to indicate statistical significance.

3. Results

3.1. Clinical investigation of the pedigree

The proband, a 47-year-old male (III:15; Fig. 1), was referred for evaluation due to obvious chest tightness and was diagnosed with HCM at 37 years of age. His brother (III:13; Fig. 1) and cousin (II:12; Fig. 1) died of SCD at 35 and 30 years of age, respectively, both at approximately 8 AM. The proband’s father (II:3; Fig. 1) was diagnosed with HCM when he was 68 years old. His aunt and uncle (II:2 and II:5, respectively; Fig. 1) died suddenly at 49 and 59 years of age, respectively. The proband’s 4 nephews experienced SCD at 16 years of age, all at approximately 8 AM. During the follow-up period, the proband’s 16-year-old son collapsed and became unconscious while studying in class at approximately 8 AM. Electrocardiogram (ECG) revealed ventricular fibrillation, and the boy died in the emergency room.

In addition to the 8 family members who died of SCD due to HCM, 17 living family members were diagnosed with HCM by echocardiography or cardiac magnetic resonance (CMR) examination. Thus, a total of 25 persons were affected with HCM in this family. The incidence in males (56%, 14/25) was similar to that in females (44%, 11/25) at the most recent follow-up (July 2015). The basic characteristics of the pedigree are shown in Table 1.
In summary, the age of onset of HCM among the affected generation family members, SCD occurred at 8 AM in individuals 30 years of age at 8 AM. Surprisingly, among the fourth-generation family members, SCD occurred at approximately 50 to 60 years of age and in the third-generation family members at approximately 30 years of age at 8 AM. The median ages of onset were 63.5 years (range, 8 to 75 years). The median ages of onset of HCM and SCD were clearly lower in the younger generations. HCM ages of onset differed significantly between each pair of generations (Wilcoxon rank-sum test; Fig. 2) as well as among all 5 generations (P < 0.0001, Kruskal–Wallis test), SCD results, and prognoses were further analyzed. Within this family (Table 3), 12 individuals carried MYH7-A719H, and 16 carried MYOZ2-L169G. Among the 12 subjects who were clinically

**Table 1**

| Generation | Number of subjects | Number with HCM | Number with SCD | Number with HCM and SCD | Age at onset | Age of SCD |
|------------|--------------------|-----------------|-----------------|-------------------------|--------------|------------|
| II         | 10                 | 4               | 4               | 2                       | 63.5 (25.5, 71.5) | 53.5 (40.0, 59.0) |
| III        | 33                 | 9               | 4               | 2                       | 38.5 (25.5, 42.5) | 32.5 (30.0, 35.0) |
| IV         | 27                 | 12              | 5               | 5                       | 18.0 (14.0, 19.0) | 16.0 (16.0, 16.0) |
| V          | 2                  | 0               | 0               | 0                       | 0             | 0          |
| Total      | 72                 | 25              | 13              | 9                       | 28.0 (18.0, 44.0) | 16.0 (16.0, 35.0) |

Age is presented as medians and quartiles. HCM = hypertrophic cardiomyopathy, SCD = sudden cardiac death.

**Table 2**

| Gene     | Chromosome | Full gene name | Exon | DNA change | Amino acid change | Codon change | Published/de novo | Published before/de novo |
|----------|------------|----------------|------|------------|-------------------|--------------|--------------------|--------------------------|
| MYH7     | 14         | Myosin, heavy chain 7, cardiac muscle, beta  | 3    | 2155C>T    | Arg719Trp          | Cgg/Tgg      | Published          | Published before         |
| MYOZ2    | 4          | Myozenin 2     | 4    | 505A>C     | Lys169Gln          | Aaa/Caa      | De novo            | De novo                  |
| DNAJC19  | 3          | DnaJ (Hsp40) homolog, subfamily C, member 19| 3    | 59G>A      | Arg20His           | Cgg/Am       | De novo            | De novo                  |
| C7NNA3   | 10         | Catenin (cadherin-associated protein), alpha 3 | 2    | 2441T>A    | Leu814*            | Taa/Ta       | De novo            | De novo                  |
| NEBL     | 10         | Nebulette      | 2    | 1286C>T    | Ser429Leu          | Taa/Ta       | De novo            | De novo                  |
| TTN      | 2          | Titin          | 2    | 90407T>C   | Ile30136Thr        | Taa/Caa      | De novo            | De novo                  |

3.2. Genetic anticipation

In this family, the median age of onset of HCM was 28.0 years (range, 8–75 years). The median ages of onset were 63.5 years among the second-generation family members, 38.5 years among the third-generation members, and 18.0 years among the fourth-generation members. The age of onset of HCM differed significantly between each pair of generations (Wilcoxon rank-sum test; Fig. 2) as well as among all 5 generations (P < 0.0001, Kruskal–Wallis test; Fig. 2). SCD occurred in the second-generation family members, 38.5 years among the second-generation family members, 38.5 years among the third-generation members, and 18.0 years among the fourth-generation members. The age of onset of HCM differed significantly between each pair of generations (Wilcoxon rank-sum test; Fig. 2) as well as among all 5 generations (P < 0.0001, Kruskal–Wallis test; Fig. 2). SCD occurred in the second-generation family members, 38.5 years among the third-generation members, and 18.0 years among the fourth-generation members. The age of onset of HCM differed significantly between each pair of generations (Wilcoxon rank-sum test; Fig. 2) as well as among all 5 generations (P < 0.0001, Kruskal–Wallis test; Fig. 2).

**Figure 2.** The median age of onset of HCM and median age of SCD across generations. The ages of onset of HCM and SCD were clearly lower in the younger generations. HCM = hypertrophic cardiomyopathy, P<0.10 = P value between generations II and III (Wilcoxon rank-sum test), P<0.05 = P value between generations III and IV (Wilcoxon rank-sum test), P<0.01 = P value among all generations (Kruska–Wallis test), SCD = sudden cardiac death.

3.3. WGS results

WGS analysis revealed the presence of heterozygous mutations in 2 distinct sarcomere genes in the 4 affected individuals: 2 missense mutations were detected in MYH7 (c.2155C>T in exon 3, A719H) and MYOZ2 (c.505A>C in exon 4, L169G). Furthermore, a heterozygous missense mutation in DNAJC19 (c.39G>A in exon 3, A20H) and a heterozygous nonsense mutation in C7NNA3 (c.2441T>A in exon 2, Leu814*). These mutations were detected in the proband. In addition to these 4 mutations, heterozygous missense mutations in TTN (c.90407T>C in exon 2, I30136Thr) and NEBL (c.1286C>T in exon 2, S429Leu) were identified in the proband’s son (Table 2). Only MYH7-A719H has been previously reported in association with HCM.[12,13] The proband’s 20-year-old daughter (IV:14; Fig. 1) carried only the MYH7-A719H mutation and was clinically unaffected, with normal ECG and echocardiogram findings. The echocardiogram results and corresponding mutations observed in the 3 immediate generations are shown in Fig. 3.

In addition to SNPs, a large deletion SV (∼400bp) was identified in the intragenic region between the MYH7 and NGLDN genes in 4 of the subjects with the HCM phenotype by WGS. However, this SV was not detected in the phenotype-negative individual IV:14.

3.4. Genotype–phenotype correlations

To determine the genotype–phenotype relationship as well as the pathogenesis associated with each of the new mutations identified in this family, the subjects’ clinical features, ECG examination results, and prognoses were further analyzed. Within this family (Table 3), 12 individuals carried MYH7-A719H, and 16 carried MYOZ2-L169G. Among the 12 subjects who were clinically
diagnosed with HCM, 7 carried both MYH7-A719H and MYOZ2-L169G, 4 had only MYH7-A719H, and 1 did not possess either mutation. Interestingly, sequencing of the MYH7 gene in all family members revealed that those who carried only the MYH7 mutation had mild LV hypertrophy or normal heart function and morphology, and all experienced only chest discomfort or no symptoms at all after activities. Twenty-four-hour Holter monitoring revealed very mild premature ventricular or atrial contractions, and ECG indicated ST-T abnormalities. By contrast, the 7 patients with both MYH7-A719H and MYOZ2-L169G had more serious symptoms, commonly complaining of palpitation and dyspnea. During the follow-up period, 1 of these
subjects experienced SCD, and another suffered from myocardial infarction without obvious hyperlipidemia. Ten of the subjects who carried only the MYOZ2 mutation showed no LV hypertrophy, abnormal ECG or echocardiographic findings, or discomfort. Compared with subjects with only MYH7-A719H or MYOZ2-L169G mutation, patients with both the MYH7-A719H and MYOZ2-L169G mutations had the largest median left atrial diameter (Kruskal–Wallis test, P = 0.015) and the highest frequency of cardiovascular events (Fisher exact test, P = 0.007). Using the HCM Risk-SCD formula, we found that individual IV:13 possessed the highest probability of experiencing SCD among all family members. Family members with both MYH7-A719H and MYOZ2-L169G mutations also showed the greatest median probability of SCD at 5 years (Kruskal–Wallis test, P = 0.033). The potential risks of SCD for all individuals in the family were calculated and are shown in Table 3.

### 4. Discussion

Genetic anticipation is a characteristic of autosomal dominant diseases. It has been previously described in HCM, but its genetic basis has not been reported. It has been suggested that the age of onset alone may not be a valid criterion for detecting anticipation in patients with complex diseases. For example, medical care is more accessible to younger generations, and the sensitivity of diagnostic tools has improved over time. Thus, aggravated diseases can be distinguished based on the anticipated age of disease and for identifying other family members who are at risk of developing it. In our study, we first selected a rare mutation by filtering our data through comprehensive databases. We then used new software and techniques (e.g., SIFT and PolyPhen-2) to predict protein structural configurations and functional alterations. By performing these steps, we increased the chance that the identified mutations were causative or, at the very least, modulators of the HCM phenotype. The mutations were cosegregated with the HCM phenotype within the study family, and finally, we determined whether each mutation was likely pathogenic or nonpathogenic based on the cosegregation results.

#### 4.1. Potential mechanisms underlying genetic anticipation in the study HCM family

Genetic anticipation can result from events such as trinucleotide repeat expansion, mitochondrial alterations, and changes in gene expression.
dosage. The generational expansion of trinucleotide repeats that occurs during meiosis and gametogenesis represents a molecular mechanism explaining the earlier onsets and worse prognoses of affected individuals observed in successive generations of families with several neurodegenerative disorders, including Huntington chorea and spinocerebellar ataxia.[18] Other potentially implicated mechanisms include mitochondrial heteroplasmy or the aberrant expression of modifier genes that segregate independently of the disease gene.[19] Alterations in gene dosages resulting from dominant mutations can also explain anticipation. Multiple gene mutations may be associated with more severe symptoms and a worse prognosis, such as markedly increased risks of rapid end-stage progression and ventricular arrhythmia in HCM patients. Moreover, heterozygotes exhibit incomplete penetrance and may develop late-onset disease, whereas homozygotes and compound heterozygotes exhibit accelerated disease processes, leading to early onset or premature sudden death.[20] In the present study, we conducted WGS analysis to examine genomic variations in 5 members of 3 successive generations of an HCM family who exhibited clear signs of anticipation and a specific phenotype, SCD. The WGS results showed that the number of gene mutations was increased in the younger generation; therefore, the anticipation that occurred in our study might be explained by the gene dosage theory. HCM patients with double or triple gene mutations exhibit extensive cardiac remodeling, including restrictive physiology, atrial dilation, and systolic dysfunction and require cardiac transplantation.[21,22] Multiple sarcomere mutations have been associated with the risk of sudden death, even in the absence of conventional risk factors.[23] In the family studied in this report, an increased number of mutations was associated with a younger age of onset and aggravated disease severity. Moreover, although both sarcomere gene mutations (MYH7 and MYOZ2) were present in autosomal genes, double mutations in these genes were detected only in males. This finding might have been a coincidence, but it could help to explain why males exhibited more severe symptoms and worse prognoses. The presence of multiple abnormal myofilament proteins resulting from complex combinations of gene mutations may be associated with more profound disruption of sarcomere mechanics and myocardial energetics, in addition to cardiomyocyte dysfunction. This may potentially explain the effects of multiple mutations in these patients.[24]

4.2. Importance of the MYOZ2-L169G mutation
MYOZ2 encodes a protein belonging to the myozin family, which includes Z-disk proteins that are exclusively present in striated muscles that can cause HCM by activating the calcineurin pathway.[25] or that function independently of calcineurin activity in the heart.[26] In our study, all subjects who carried the MYOZ2-L169G mutation were heterozygotes. Ten of these subjects carried only this mutation, and their clinical manifestations and ECG findings were normal, supporting the notion that MYOZ2-L169G had few pathogenic effects in this family. However, among the 3 carriers of MYH7-A719H (determined using WGS), the phenotype-negative daughter (IV:14) did not carry the MYOZ2-L169G mutation, whereas the phenotype-positive grandfather (II:3), father (III:15), brother (IV:13), and cousin (IV:22) carried it. Moreover, the family members who carried both the MYH7 and MYOZ2 mutations had more severe symptoms, including SCD, than those with only the MYH7 mutation. It can be inferred that MYOZ2 may play a modifying role in HCM by affecting the penetrance or degree of performance of the MYH7 gene. However, the cumulative effects of the mutations on the disease phenotype may represent a new feature of HCM. Therefore, MYOZ2 could be an additive gene, whereas MYH7 could be a major gene in HCM.

4.3. Potential effects of SVs on HCM
The effects of abnormal SVs on HCM have not been reported. A large deletion (~400 bp) was detected in 4 of the phenotype-positive family members in this study (II:3, III:15, IV:13, and IV:22), but it was not identified in the phenotype-negative individual IV:14. More interestingly, this SV was associated with the presence of the MYOZ2-L169G mutation, which might be evidence of a potential interaction between different mutations. Unbalanced gene rearrangements, such as insertions, deletions, and tandem duplications, may lead to changes in gene dosage, which can affect the carrier phenotype.[27] An SV in a noncoding region may substantially alter the position of a regulatory element that controls gene expression or affects its regulation (i.e., position effects), thereby modulating the expression of the gene. An SV can also affect gene expression by changing local chromatin structure.[28] In addition, although some SVs do not result in phenotypic alteration, they can impact disease susceptibility in affected individuals. The SV detected in this family might have affected the phenotypic severity. Therefore, SVs and other types of mutations, such as indels and copy number variations, should be considered in HCM.

4.4. Possible explanation for the heterogeneity observed in HCM
The CTNNA3 gene mutation can cause arrhythmogenic right ventricular cardiomyopathy, which is characterized by arrhythmia and juvenile sudden death.[29] The ECG findings for the patients who experienced SCD in this study showed clear signs of ventricular fibrillation attack, which might be the result of the expression of an arrhythmogenic gene mutation. Using high-throughput sequencing, Lopes et al found that approximately 43% of HCM patients carried variants in genes associated with arrhythmogenic right ventricular cardiomyopathy and ion channel diseases, and these variants may explain why some patients with HCM suffer from symptoms ranging from malignant arrhythmia to SCD.[17] The NEBL gene mutation has been associated with endocardial fibroelastosis and dilated cardiomyopathy.[30] The DNAJC19 gene has also been associated with dilated cardiomyopathy.[31] Although the significance of the mutations in the 2 genes identified in the current study were more difficult to assess, the variants observed in this pedigree occurred at a frequency of <0.5% in the 1000 Genomes Project. These findings suggest that at the very least, these mutations partly modulated the patients’ phenotypes.[17] The presence and effects of these mutations might explain the earlier and more severe symptoms that were observed and might even contribute to the heterogeneity observed in HCM.

4.5. Potential explanation of the SCD phenotype
The HCM Risk-SCD model has improved risk stratification in HCM for the primary prevention of SCD. The results obtained using this model are in agreement with the observed SCD risks in this family. Individual IV:13 exhibited the highest 5-year risk of developing SCD, and he experienced SCD at 16 years of age.
According to the recommendations of this risk model,\textsuperscript{116} individuals IV:12 and IV:22 should consider cardioverter defibrillator implantation. The increased sympathetic activity that occurs in the morning or during sports may cause hyperfunctionality of the circulatory system, which can include coronary artery constriction and tachycardia, and these symptoms may lead to myocardial ischemia and malignant arrhythmia. This phenomenon may explain the finding that all cases of SCD in this study occurred at approximately 8 A.M. However, it is difficult to explain why SCD occurred in the third-generation family members while they were in their 30s, whereas among the fourth-generation family members, SCD occurred only in 16-year-old males. It remains unknown whether these findings were an incredible coincidence or were triggered by changes such as altered hormone levels,\textsuperscript{32} similar degrees of myocardial fibrosis,\textsuperscript{33} the early activation of cellular and molecular responses to or the expression of some mutations,\textsuperscript{34} or the excitation of the sympathetic nervous system. Thus, the mechanism potentially underlying SCD initiation is unknown and requires further study.

Moreover, in young subjects with SCD, it is not any more common to find HCM than a structurally normal heart at the time of death, and confirmation of SCD from arrhythmogenic causes such as channelopathies (long-QT syndrome, short-QT syndrome, etc.) may be required.\textsuperscript{35,36} It is possible that an individual’s profile of common cardiac channel polymorphisms might mediate pathogenic susceptibility to arrhythmia in the setting of HCM.\textsuperscript{35,37} Further examination and gene sequencing beyond HCM would be useful in familial heart disease with SCD.

Finally, HCM is still the most important cause of SCD in competitive athletes\textsuperscript{38,39}, thus, cardiovascular screening is important for young athletes and relatives from HCM families to prevent the risk of HCM-associated SCD.\textsuperscript{38} Echocardiography is the most commonly used noninvasive technique in HCM. A comprehensive approach is recommended for the assessment of LV diastolic function and filling pressures in patients with HCM, including speckle tracking, E/e’ ratio, LA volume index, and pulmonary vein atrial reversal velocity,\textsuperscript{40,41} to potentially predict adverse outcomes, including death, cardiac arrest, and ventricular tachycardia. Moreover, new parameters such as ultrasound deformation imaging and 2-dimensional strain could provide more sensitive detection of regional myocardial motion and deformation\textsuperscript{42} and quantification of global and regional systolic dysfunction and pathological LV hypertrophy. CMR is a more accurate method for diagnosing HCM due to its unrivaled capability to assess LV hypertrophy and LV fibrosis. A recent study indicated that combined CMR high-resolution quantitative assessment of myocardial perfusion and LV fibrosis is feasible in patients with HCM, in addition to late gadolinium enhancement.\textsuperscript{43} This method could provide more accurate information on the ischemic burden, which may have potential significance in the outcome of HCM.\textsuperscript{44} Other parameters that are considered important markers for cardiovascular prognosis and therapeutic responses, such as LV mass or LV hypertrophy, should also be measured by CMR in HCM.\textsuperscript{35,43}

4.6. Limitations

Some limitations of this study should be considered. First, comprehensive LV parameters were not determined by echocardiography in the clinic in this work, and CMR was not performed in all family members because of financial limitations. Second, as we lacked a simple method, the SVs detected by WGS were not verified using another technique. Third, we filtered the regions containing noncoding and synonymous variants, which may have resulted in the loss of additional useful genetic information. Therefore, further studies of mutations in other gene regions are needed. Fourth, this study is based on the pedigree of 1 family, and more pedigrees of families with HCM are needed to validate these results. Moreover, this study was confined to the examination of cosegregation in the pedigree, and no functional experiments were performed.

5. Conclusions

Genetic anticipation was observed in the HCM family evaluated in this study. Multiple gene mutations were determined to be the most likely causes of genetic anticipation in the HCM patients in this family. These mutations affected the phenotypes and prognoses of these patients. The MYOZ2-L169G mutation alone was not found to be pathogenic, but it did appear to play a modifying role in HCM.

Acknowledgment

We thank Dr Zunsong Hu for assisting with the statistical analyses.

References

[1] Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064–75.
[2] Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012;60:705–15.
[3] Roma-Rodrigues C, Fernandes AR. Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy. Appl Clin Genet 2014;7:195–208.
[4] Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 2004;116:14–8.
[5] McNamis MG. Anticipation: an old idea in new genes. Am J Hum Genet 1996;59:973–9.
[6] Gregor P, Cerny M. Genealogic study of hypertrophic cardiomyopathy in the Czech population. Vnitr Lek 1992;38:326–31.
[7] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;58:e212–60.
[8] Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1–39.e4.
[9] Alfarese AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med 2015;17:880–8.
[10] Kimura A. Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet 2015;60:41–50.
[11] Lopes carbo CG, Tester DJ, Maleczewski JJ, et al. Confirmation of cause and manner of death via a comprehensive cardiac autopsy including whole exome next-generation sequencing. Arch Pathol Lab Med 2014;138:1083–9.
[12] Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994;93:280–5.
[13] Poutanen T, Tikanoja T, Jaakelainen P, et al. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes. Am Heart J 2006;151:725–721–9.
[14] Alda M, Grof P, Ravindran L, et al. Anticipation in bipolar affective disorder: is age at onset a valid criterion? Am J Med Genet 2000;96:804–7.
[15] Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010;362:1181–91.
[16] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79.
[17] Lopes LJ, Zelavsky A, Syriss P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet 2013;50:228–39.
[18] Sameena M, Asma S, Fauzia K, et al. DNA trinucleotide repeat expansion in neuropsychiatric patients. Med Sci Monit 2003;9:RA237–45.
[19] Porekaj P, Moses L, Montimurro JS, et al. Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism. BMC Neuro 2005;5:4.
[20] Ortiz MF, Rodriguez-Garcia MI, Hermida-Prieto M, et al. A homozygous MYBPC3 gene mutation associated with a severe phenotype and a high risk of sudden death in a family with hypertrophic cardiomyopathy. Rev Esp Cardiol 2009;62:572–5.
[21] Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79.
[22] Poorkaj P, Moses L, Montimurro JS, et al. Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism. BMC Neuro 2005;5:4.
[23] Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy. Circ Res 2007;100:766–71.
[24] Ruggiero A, Chen SN, Lombardi R, et al. Pathogenesis of hypertrophic cardiomyopathy caused by myozin 2 mutations is independent of calcineurin activity. Cardiovasc Res 2013;97:44–54.
[25] Osio A, Tan L, Chen SN, et al. Myozin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res 2007;100:766–8.
[26] Rodriguez-Revenga L, Milla M, Rosenberg C, et al. Structural variation in the human genome: the impact of copy number variants on clinical diagnosis. Genet Med 2007;9:600–6.
[27] Kleinjan DJ, van Heyningen V. Position effect in human genetic disease. Hum Mol Genet 1998;7:1611–8.
[28] van Hengel J, Calore M, Bause B, et al. Mutations in the area composita protein alphaT-catenin are associated with arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2013;34:201–10.
[29] Purevjav E, Varela J, Morgado M, et al. Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J Am Coll Cardiol 2010;56:1493–502.
[30] Kleinjan DJ, van Heyningen V. Position effect in human genetic disease. Hum Mol Genet 1998;7:1611–8.
[31] Richter-Dennerlein R, Korwitz A, Haag M, et al. DNAJC19, a mitochondrial cochaperone associated with cardiomyopathy, forms a complex with prohibitins to regulate cardiolipin remodeling. Cell Metab 2014;20:158–71.
[32] Olivoto I, Maron MS, Adabag AS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:480–7.
[33] Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552–63.
[34] Kim JB, Porreca GJ, Song L, et al. Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 2007;316:1481–4.
[35] Tester DJ, Ackerman MJ. Sudden infant death syndrome: how significant are the cardiac channelopathies? Cardiovasc Res 2005;67:388–96.
[36] Ackerman MJ. Cardiac channelopathies: it’s in the genes. Nat Med 2004;10:463–4.
[37] McNamara WJ, Calvert AJ. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation 1989;80:1489–92.
[38] Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2007;115:1643–55.
[39] Leschik R, Dvorak B, Foshag P, et al. Pre-participation and follow-up screening of athletes for endurance sport. J Clin Med Res 2015;7:385–92.
[40] Nagsh SF, Smiothba OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277–314.
[41] Leschik R, Lrittwitz H, Dvorak B, et al. Echocardiographic evaluation of left atrial mechanics: function, history, novel techniques, advantages, and pitfalls. Biomed Res Int 2015;2015:765921.
[42] Cikir M, Sutherland GR, Anderson LJ, et al. The role of echocardiographic deformation imaging in hypertrophic myopathies. Nat Rev Cardiol 2010;7:384–96.
[43] Armstrong AC, Gjesdal O, Almeida A, et al. Left ventricular mass and hypertrophy by echocardiography and cardiac magnetic resonance: the multi-ethnic study of atherosclerosis. Echocardiography 2014;31:12–20.
[44] Villa AD, Sammut E, Zarriabah N, et al. Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson 2016;18:4.
[45] Butz T, van Buren F, Mellwig KP, et al. Two-dimensional strain analysis of the global and regional myocardial function for the differentiation of pathologic and physiologic left ventricular hypertrophy: a study in athletes and in patients with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 2011;27:91–100.